Announced details
Advanced, relapsed and refractory solid tumors, particularly ovarian cancer
Partial responses (PR) were observed in 3 patients with ovarian cancer, and MYC gene amplification was confirmed in 2 of them
Administered to a total of 46 patients with solid tumors
Relationship with the academic journal that published the clinical trial results for rogocekib developed by the Company
An academic journal publishing clinical and translational cancer research that connects basic research with clinical practice
jRCT2080224127
The Company believes that these results support the potential for future expansion of the indications for solid tumors
The company does not address Contract Value / Offering price.
Clinical Cancer Research、jRCT2080224127
| Item | Details |
|---|---|
| Names of Products / Services Covered | rogocekib（CTX-712） |
| Counterparty | Clinical Cancer Research |
| Counterparty overview | An academic journal publishing clinical and translational cancer research that connects basic research with clinical practice |
| Relationship with the Company | Relationship with the academic journal that published the clinical trial results for rogocekib developed by the Company |
| Applicable area | Advanced, relapsed and refractory solid tumors, particularly ovarian cancer |
| Registration number and expiry date | jRCT2080224127 |
| Quantitative Effects | Partial responses (PR) were observed in 3 patients with ovarian cancer, and MYC gene amplification was confirmed in 2 of them |
| Usage history | Administered to a total of 46 patients with solid tumors |
| Impact on Business Performance | The Company believes that these results support the potential for future expansion of the indications for solid tumors |
| Source | Clinical Cancer Research、jRCT2080224127 |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The final results from the solid tumor cohort were published in Clinical Cancer Research. The Company believes that these results support the potential for future expansion of the indications for solid tumors, including ovarian cancer.